Can-Fite BioPharma (NYSE:CANF) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note published on Saturday morning. The firm issued a hold rating on the stock.

Can-Fite BioPharma Trading Up 0.9 %

Shares of NYSE:CANF opened at $2.35 on Friday. The stock has a market cap of $8.32 million, a PE ratio of -1.31 and a beta of 1.53. Can-Fite BioPharma has a 1-year low of $1.52 and a 1-year high of $3.33. The stock’s fifty day simple moving average is $2.14 and its two-hundred day simple moving average is $2.15.

Can-Fite BioPharma (NYSE:CANF) last released its earnings results on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 111.16% and a negative net margin of 1,027.46%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. On average, sell-side analysts forecast that Can-Fite BioPharma will post -0.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Can-Fite BioPharma

Large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in Can-Fite BioPharma during the 4th quarter valued at about $340,000. Schechter Investment Advisors LLC purchased a new position in shares of Can-Fite BioPharma during the fourth quarter worth about $44,000. Finally, Virtu Financial LLC purchased a new position in shares of Can-Fite BioPharma during the second quarter worth about $52,000. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.